DRUG · Mapped RxNorm record
Pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Dostarlimab
Normalized identity: dostarlimabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Belrestotug
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Nelistotug
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancer, Non-Small Cellunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
DostarlimabDRUG · verified · RxNorm: dostarlimab
BelrestotugDRUG
NelistotugDRUG
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
iTeos Therapeuticscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05565378 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.